1. Inicio
  2. Publicaciones
  3. Update of the SEIOMM clinical guideline of osteoporosis: Abaloparatide.

Update of the SEIOMM clinical guideline of osteoporosis: Abaloparatide.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Peris, P
  • Martinez, G
  • en nombre de la Comision de Redaccion de las Guias de Osteoporosis de la
  • SEIOMM

Unidades

Abstract

INTRODUCTION: Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options. OBJECTIVE AND RESULTS: This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines. CONCLUSION: Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.

Copyright © 2025. Published by Elsevier España, S.L.U.

Datos de la publicación

ISSN/ISSNe:
2254-8874, 2254-8874

Revista clinica espanola  

Tipo:
Article
Páginas:
502338-502338
PubMed:
40675329
Factor de Impacto:
0,000 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Abaloparatida; Abaloparatide; Clinical guidelines; Fracturas; Fractures; Guías clínicas; Osteoporosis

Cita

Compartir